Imatinib
Sign in to save this workspacePrimary targets: BCR_ABL, ABL1, ABL2_ARG · FDA status: FDA Approved
Selectivity scorecard
KISS
99.00
Gini
0.718
CATDS
0.033
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Imatinib. Strongest target: PDGFRA at 98.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PDGFRA | 98.9% | 1.1% |
| 2 | DDR1 | 94.5% | 5.5% |
| 3 | FMS | 92.2% | 7.8% |
| 4 | LCK | 90.2% | 9.8% |
| 5 | DDR2 | 87.7% | 12.3% |
| 6 | ABL1 | 86.2% | 13.8% |
| 7 | LYN | 80.6% | 19.4% |
| 8 | RAF1 | 74.0% | 26.0% |
| 9 | PDGFRB | 70.7% | 29.3% |
| 10 | ABL2_ARG | 63.1% | 36.9% |
| 11 | C_KIT | 62.1% | 37.9% |
| 12 | PDK2_PDHK2 | 43.2% | 56.8% |
| 13 | ARAF | 42.8% | 57.2% |
| 14 | BRAF | 39.8% | 60.2% |
| 15 | ROS_ROS1 | 39.8% | 60.3% |
| 16 | FGR | 38.9% | 61.1% |
| 17 | CAMKK2 | 38.6% | 61.4% |
| 18 | PKG2_PRKG2 | 31.0% | 69.0% |
| 19 | BLK | 30.4% | 69.6% |
| 20 | ERN1_IRE1 | 29.8% | 70.2% |
Selectivity landscape
Where Imatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Imatinib.
Annotations
Sign in to read and post annotations.
Loading…